RU1812993C - Method for parodontitis treatment - Google Patents

Abstract

Usage: the invention relates to medicine, dentistry, and in particular to the treatment of periodontitis. Objective: to increase the effectiveness and reduce the period of treatment of periodontitis. SUMMARY OF THE INVENTION: Gauze swabs moistened with 1-2 ml of an aqueous pilastine solution, which is prepared by dissolving the contents of the ampoule in distilled water, are introduced into dental gingival pockets daily for 5-7 days for 5-7 hours: the first two days from 600 to 850 EU, on the 3-4th day - from 850 to 1600 EU and in the next 3-6 days from 2000 to 2400 EU. Positive effect: edema and bleeding of the gums disappear in 82% of patients, the duration of treatment is 3-7 days; the use of the method will reduce the duration of treatment by 2 times, increase the number of recovered patients by 30%. 2 tab.

Description

The invention relates to medicine, dentistry, and in particular to the treatment of periodontitis.

The aim of the invention is to increase the effectiveness and shorten the treatment of periodontitis.

This goal is achieved by the fact that in this method, gauze tampons moistened with 1-2 ml of an aqueous solution of pilastin, which is prepared by dissolving the contents of the ampoule in distilled water, are introduced into the gingival pockets daily for 5-7 days for 5-7 hours calculation: in the first two days from 600 to 850 EU. on days 3-4, from 850 to 1600 EU and in the next 3-6 days from 2000 to 2400 EU (concentration is taken according to VFS 42-182 BC-88). The procedure is repeated daily until the edema and bleeding of the gums disappear.

The course of treatment is 5: -7 (3-10) days. If necessary, treatment can be repeated after 1 month or at a later date.

Pilastine is approved for use in public health practice as a therapeutic drug (order No. 832 of the USSR Ministry of Health on 11/21/88) and a prophylactic vaccine (order No. 903 of 11/16/1973). The drug is produced by the All-Union NIPCI Microbe for the treatment of alopecia ariata according to VFS 42-56 VF-87 (the instructions for use were approved on 08.25.88), and as a vaccine according to VFS 42-56 VS-87 (the instructions for use were approved on 10.22.86 g. )

Pilastine is an odorless, grayish-yellow powder, after solution

"L

you

with

Rhenium in distilled water is a yellowish brown liquid with a slight opalescence, odorless.

The preparation is dosed in human doses for subcutaneous administration and is expressed in units of antitoxin binding (EC).

One man-dose for subcutaneous administration is 2400 EC; for a single rub, for external use, 5 man-doses or 12000 EC are used.

In experiments on rabbits, guinea pigs, white mice, and frogs with cutaneous, intradermal, subcutaneous, intravenous, intragastric, conjunctival and intraocular administration daily for 21 days, 1200 EC and 24000 EC pylastine did not elicit acute and chronic toxicity.

Clinical trials of volunteers with the oral administration of (140 ± 20) human doses of pilastine or (350,000 ± 50,000) EC showed that the drug was harmless. The drug did not have a side effect when rubbed into the skin of people daily for 7 days at 35-40 person doses (84000-96000 EC). The drug has been used since 1973 ;: for vaccination and revaccination of adults and children from 7 years of age. Tens of thousands of people have been vaccinated during this period. Complaints about unacceptable adverse reactions have been reported .; :;

Pilastine is a biologically active substance, an immunostimulant. .

Under the influence of pylastine (cholerogen-toxoid (cholera vaccine) in humans and laboratory animals, it intensifies with a non-specific immunobiological reaction, which manifests itself in changes in protein metabolism; changes in the activity of enzyme glycolysis, pentose phosphate pathway and Krebs cycle; change in pbpule th and subpopulational composition of lymphocytes; change in bioenergetic processes - increase in the energy charge of the adenyl system of blood and lymphocytes ...;;..: -: .....; -..

The authors carried out a large experimental work, allowing us to identify the intervals of dose parameters of pylastine at different treatment times (Table 1),

For each scheme was; 4 people were treated. As a result, it was found that the daily dose of pilastine in the first two days cannot be less than 600 EU, because a dose of 300 EU caused a weak effect (swelling and bleeding of the gums decreased in the late stages on the 7-10th day) and not more than 850 EU, because at this dose, no significant

enhancing the therapeutic effect compared to the previous (600 EU) effective dose. On the third and fourth days of treatment, the optimal single dose of pilastin should be 1200 EC, but not less than 850 EC, because it provided a somewhat weak therapeutic effect of rib to the terms of the disappearance of signs of the disease compared with a dose of 1200 EC, and not more than 1600 EC, because dose 1600

EU caused a similar effect with a dose of 1200 EU. On the third to tenth day of treatment, the optimal daily dose of pilastin should be from 2000 EC to 2400 EC and not more than 2700 EC, at which the effect is increased by

the rate of disappearance of pathological symptoms compared with the previous dose is not recorded.

The method is carried out as follows. :;: ;; . -: /. - /:; -; H ::,; :,.

After treating the oral cavity with an antiseptic (solutions of furacidin or furazolidone) and manually removing the supra-subgingival dental deposits, gauze turundas moistened with 1-2 ml of water are introduced into the gingival pocket for 5-7 days every day for 5-7 hours a pilastin solution containing from 600 to 850 EC in the first two days, from 800 to 1600 EC on the 3-4 days, and from 2000 to 2400 EC in the remaining 3-6 days. Turunds cover with paraffin.

In accordance with VFS 42-182 BC-88, pilastin is released in ampoules of 10 ml of protein. The activity of the preparation is dosed in binding units (EC). One human dose for subcutaneous administration is 2400 EC, for external use (rubbing into the skin - 12000 EC). The ampoule indicates the number of human doses for subcutaneous administration.

We used a series of pylastine containing 40 man-doses or 96000 EC in an ampoule for the treatment of patients with periodontal disease according to the three options A, 8 and C described above.

To prepare working solutions of pylastin in the first 2 days of treatment, the contents of the first ampoule were dissolved in 113 ml of a sterile 0.9% sodium chloride solution and a solution was obtained in which 1 ml was

850 EU; 8 ml of 0.9% sodium chloride was added to 20 ml of the resulting solution, and a solution containing 1 ml of 600 EC was obtained, then it was diluted 2 times with 300 EC in 1 ml. On the 3rd and 4th days of treatment, the contents of the second ampoule

dissolved in 60 ml of the same solvent, and a solution was obtained in which 1 ml of which was 1600 EC, 3 ml of solvent was added to 10 ml of this solution, and 1200 EC in 1 ml was obtained. To 10 ml of Pilastine solution (1600 EC / ml)

added 9 ml of solvent and got 850

EC in 1 ml. In the next 5-10 days of treatment, the contents of one ampoule were dissolved in 35.5 ml of a sterile 0.9% sodium chloride solution and a solution was obtained, in 1 ml of which there were 2700 EC pilastine, and the other in 40 ml "(2400 EC c. 1 ml) and the third in 48 ml (2000 EC / ml).

The set of essential features developed by the inventors and given in the characterizing part of the formula is necessary and sufficient to unambiguously obtain the claimed positive effect of increasing the efficiency of the method and shortening the treatment time.

The known technical solution (prototype) provides a therapeutic effect in 50-60% of patients, the duration of treatment is 7-14 days, the claimed technical solution provides a clinical effect in 82% of patients, including 35% of patients who cannot be treated in a known manner; the duration of treatment is 3-7 days.

Example 1. K.L.A., 32 years old. Clinical diagnosis: chronic generalized periodontitis of moderate severity in the acute stage. Disease duration b years. Remissi came in 1.5-2 months. Previously carried out in a known manner, the treatment was not effective. Complaints of bleeding gums, pain and itching in the gums. Objectively: SDS gingival papillae are edematous, bleeding (CD), hygiene index (IG) -2, pathological gingival pocket (PZDK) - 4 mm, tooth mobility (P) - 1-I degree, papillary-marginal-alveolar index (RMA) -45%.

Scheduled treatment with pilastin according to scheme C (max). The first two days, the gingival pockets are tamped with turundas moistened with 1 ml of pilastine containing 850 EC, in the next 2 days - 1600 EC and in the remaining three days - 2700 EC / ml. On the second day of treatment, pain, itching, tooth mobility disappeared, from the 3rd day of treatment, swelling and bleeding of the gums decreased, a significant improvement occurred on the 5th day after the start of treatment: bleeding and itching stopped, the papillae were pale pink, IG - 1. RMA - 15%, SP - 0. There was no side effect of pylastine and complications on its administration. The sick leave was issued for 5 days. After 6 months, no relapse was observed during examination.

The method of treating a patient according to scheme b (max.) Showed that a positive effect was achieved from the second day of treatment, and after 5 days there was a significant improvement.

Example 2. K.I.N., born in 1959 Diagnosis: clinical chronic generalized periodontitis of moderate severity in the acute stage. The duration of zebolev is 5 or more than 10 years. Remissi through 2 mine. Objectively: the gingival papillae are sharply edematous, bleeding, P - IHII art. PZDK - 5 mm. exposure - 1/3 of the roots, IG - 4. Appointed treatment with pilastine according to scheme A (option 10 min.). The first two days on turundas were applied 1 ml of an aqueous solution of pilastine at a concentration of 300 EC, on the third and fourth days - 850 EC and on subsequent days - 2000 EC. After 3 days of treatment, the patient disappeared

5 pain and itching, after 4 days the CD decreased, after 5 days the pain disappeared, after 7 days the gingival papillae became pale pink. After 8 days, PZDK - 3 mm, P - I-II st., IG -1, i.e. a significant improvement has come. The sick leave issued for 8 days. There were no complications on the use of pilastine. Inspection after 6 months of remission no.

The method of treating a patient with pylastin according to Scheme A (min.) Showed that a positive 5 effect was achieved from the third day, and a significant improvement was achieved by the 8th day.

Example 3. S.A.A .. born in 1945. Clinical diagnosis: chronic generalized periodontitis of moderate severity in the acute stage. Sick for about 12 years. Previously, it has been repeatedly treated by conventional methods. Remissions in 2-3 months. Objectively: bleeding gums, itching, soreness, gingival papillae swollen, hyperemic. RMA - 46%, PZDK - 3.5-5 mm, IG - 2. P - II st. Prescribed treatment with pilastin according to scheme B (opt.). From the second day from the start of treatment, itching, pain disappeared,

On the 3rd day, bleeding of the gums disappeared, swelling decreased, IG-1.0, PZDK-2 mm, PMA-10%, П-I degree, i.e. there has been a significant improvement. By the end of treatment (day 5), the side effects of pilastine and

5 complications during its use were not. The sick leave was issued for 5 days. Inspection through me - no remission.

An optimal treatment regimen for a patient has shown the best therapeutic

0 effect - the condition improved from the second day, and on day 3-5 the pathological signs of the disease disappeared. We have taken this variant of the treatment regimen as pilastin optimal. Take into account the positive effect

5 minutes, and max. Schemes, the range of doses recommended in the claims has been determined.

Our method has been shown in cases of human disease with periodontitis, including those that are not amenable to other traditional methods of treatment. There are no contraindications.

Application of the optimal variant of the method in the clinic showed that in comparison with the prototype selected for the basic variant, an increase in (p 0.01-0.05) efficiency by 32-40% and a reduction in treatment time by 3 times is achieved (Table 2).

In the treatment with a new method - an aqueous solution of pilastine according to the proposed scheme, the clinical effect is achieved in 82% of patients; swelling and bleeding of the papillae are already reduced by 3-4 days, PZDK, IG, P decreases, by the 5-6th day they return to normal. 50% of patients treated by a known method for up to 10 days or more did not have a positive trend in the clinical signs of the disease.

Thus, the proposed method for the treatment of perodontitis with an aqueous solution of pilestin according to the recommended scheme allows

significantly increase efficiency, reduce the period of disability and recovery of patients with persistent remission of the disease. The method is simple to implement, can be used not only in a hospital, but also in an outpatient setting, does not require additional tools and procedures. .

Claims (1)

Gain Formula A method for treating periodontitis by introducing a drug into the dentition pockets, characterized in that, in order to reduce the treatment time, the gingival pockets are injected daily for 5-7 hours with turundas containing 1-2 ml of an aqueous solution of pilastine for 3-10 days, with a concentration of pilastine of the first two days from 600 to 850 EC. for 3-4 days from 850 up to 1600 EU and subsequent days from 2000 to 2400 EU. .Table 1 The results of Studies on the choice of treatment regimens for periodontal patients proposed ...... method Note. 1 min. (A) on days 1–2, 300 EU each, on days 3–4, only 850 EUs, and days 5–10 on 2000 EUs; 2) opt. (B) - for 1 -2 days - for 600 EU, for 3 - 4 days - for 1200 EU. For 5-10 days - for 2400 EU; 3) max. (C) - on day 1-2 - for 850 EU, for day 3-4 - for 1600 EU, for day 5-10 to 2700 EU. Comparative data on the effectiveness of the proposed method of treatment with pilastin and  prototype Note. -For the base case - the treatment time, because half of the patients did not have recovery and significant improvement, for the proposed period of recovery or significant improvement. 1812993 10 Table 2